Biological Response Modifiers Influence Structure Function Relationship of Hematopoietic Stem and Stromal Cells in a Mouse Model of Leukemia

  • Basu, Kaustuv (Department of Anatomy and Cell Biology, McGill University) ;
  • Mukherjee, Joydeep (Brain Tumor Research Centre, Department of Neurosurgery, Helen Diller Family Comprehensive Cancer Centre, UCSF) ;
  • Law, Sujata (Department of Biochemistry & Medical Biotechnology, Stem Cell Research & Application Unit, Calcutta School of Tropical Medicine) ;
  • Chaudhuri, Samaresh (Department of Biochemistry & Medical Biotechnology, Stem Cell Research & Application Unit, Calcutta School of Tropical Medicine)
  • Published : 2012.06.30


Biological response modifiers (BRMs) can alter interactions between the immune system and cancer cells to boost, direct, or restore the body's ability to fight disease. Mice with ethylnitrosourea- (ENU) induced leukemia were here used to monitor the therapeutic efficacy of lipopolysaccaride (LPS), Bacillus Calmette Guerin (BCG) and sheep erythrocytes (SRBC). Flow cytometry based CD34+ positivity analysis, clonogenicity, proliferation and ultrastructure studies using scanning electron microscopy (SEM) of stem cells in ENU induced animals with and without BRMs treatment were performed. BRMs improved the stem-stromal relationship structurally and functionally and might have potential for use as an adjunct in human stem cell therapy.


  1. Ayala F, Dewar R, Kieran M, Kalluri R (2009). Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, 23, 2233-41.
  2. Baldridge MT, King KY, Boles NC, Weksberg DC, Goodell MA (2010). Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection. Nature, 465, 793-7.
  3. Basak P, Chatterjee S, Das M, et al (2010). Phenotypic alteration of bone marrow HSC and microenvironmental association in experimentally induced leukemia. Current stem cell research & therapy, 5, 379-86.
  4. Beresford JN, Owen ME (1998). Marrow stromal cell culture. Cambridge University Press, Cambridge, Eng. ; New York, Handbooks in practical animal cell biology, pp. xii, 153 p.
  5. Briancon-Marjollet A, Balenci L, Fernandez M, et al (2010). NG2-expressing glial precursor cells are a new potential oligodendroglioma cell initiating population in N-ethyl- N-nitrosourea-induced gliomagenesis. Carcinogenesis, 31, 1718-25.
  6. Can A (2007). Niche concept and the hematopoietic stem cell niches. Turkish J hematology, 24, 95-101.
  7. Chatterjee S, Basak P, Das M, et al (2009). Kinetic impairment of haemopoietic stem cells in experimentally induced leukemia and aplastic anemia: an inverse correlation. J stem cells, 4, 179-89.
  8. Chen D, Li Z, Chen T (2011). Increased expression of miR-34a in mouse spleen one day after exposure to N-ethyl-Nnitrosourea. J applied toxicol, 31, 496-8.
  9. Corocleanu M (2008). A possible "universal" cancer vaccine that might cause an immune response against emerging cancer cells that originate from any tissue. Med hypotheses, 70, 381-3.
  10. Dennis JE, Charbord P (2002). Origin and differentiation of human and murine stroma. Stem cells, 20, 205-14.
  11. Dexter TM, Allen TD, Lajtha LG (1977) Conditions Controlling Proliferation of Hematopoietic Stem-Cells Invitro. J cellular physiology, 91, 335-44.
  12. Duhrsen U, Hossfeld DK (1996). Stromal abnormalities in neoplastic bone marrow diseases. Annals of hematology, 73, 53-70.
  13. Justice MJ, Noveroske JK, Weber JS, et al (1999). Mouse ENU mutagenesis. Human molecular genetics, 8, 1955-63.
  14. Law S, Maiti D, Palit A, et al (2001) Facilitation of functional compartmentalization of bone marrow cells in leukemic mice by biological response modifiers: an immunotherapeutic approach. Immunology letters, 76, 145-52.
  15. Li Z, Li L (2006). Understanding hematopoietic stem-cell microenvironments. Trends in biochemical sciences, 31, 589-95.
  16. Meydan N, Grunberger T, Dadi H, et al (1996) Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature, 379, 645-8.
  17. Mukherjee J, Ghosh A, Sarkar S, et al (2005). T11TS/S-LFA3 induces apoptosis of the brain tumor cells: a new approach to characterise the apoptosis associated genetic changes by arbitrarily primed-PCR. Cancer letters, 222, 23-38.
  18. Nagai Y, Garrett KP, Ohta S, et al (2006). Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity, 24, 801-12.
  19. Nagasawa T, Hirota S, Tachibana K, et al (1996). Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature, 382, 635-8.
  20. Najman A, Kobari L, Khoury E, et al (1991). Suppression of normal hematopoiesis during acute leukemias. NY Academy of Sciences, 628, 140-7.
  21. Potten CS, Loeffler M (1990). Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development, 110, 1001-20.
  22. Rizo A, Vellenga E, De Haan G, Schuringa JJ (2006). Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche? Human molecular genetics 15 Spec No 2, R210-9.
  23. Stoica G (2002). ENU-induced ovarian cancer. Methods in molecular biology, 188, 305-14.
  24. Takizawa H, Regoes RR, Boddupalli CS, et al (2011). Dynamic variation in cycling of hematopoietic stem cells in steady state and inflammation. J experimental med, 208, 273-84.
  25. Vaquero J, Zurita M, Oya S (1998). Immune-cell system provides the development of extraneural tumors in the ethyl-nitrosourea model of neurocarcinogenesis. Cancer letters, 123, 95-8.
  26. Verfaillie CM (1993). Soluble factor(s) produced by human bone marrow stroma increase cytokine-induced proliferation and maturation of primitive hematopoietic progenitors while preventing their terminal differentiation. Blood, 82, 2045-53.